Novo Nordisk expects a decline in sales of up to 13 per cent this year as the Danish drugmaker competes in an increasingly crowded obesity-treatment market and faces pressure on the pricing of its ...

The maker of Ozempic is facing stiff competition from rival obesity drug companies, as well as unproven knock-offs from China ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...

The proliferation of cheaper generic drugs and more competition has already begun to bring down prices on weight-loss ...

Novo Nordisk cut its 2026 outlook after missing 2025 estimates, while Eli Lilly heads into earnings with a focus on Medicare ...

Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, has warned that profits and sales could fall by as much as 13 ...

Novo Nordisk's stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects ...

Novo Nordisk beat analyst expectations for the fourth quarter, but the result was overshadowed by softened expectations for ...

Novo Nordisk stock (NVO) plunged approximately 15% after the Danish pharmaceutical giant posted better-than-expected 2025 results but delivered a weak 2026 outlook. The company reported full-year 2025 ...

Novo Nordisk has launched a pill version of its blockbuster weight-loss drug, Wegovy. Novo Nordisk's stock plunged Tuesday ...

Eli Lilly is scheduled to report its fourth-quarter results before the market opens Wednesday. Here is what you need to know. PROFIT: Analysts polled by FactSet expect the company to post net income ...